Cambridge University and Life Technologies collaborate to set up
high throughput sequencing hub
2 December 2009
The University of Cambridge and Life Technologies Corporation
(NASDAQ:LIFE), are collaborating to make next-generation sequencing
technology available to the European research and clinical communities
through the Eastern Sequence and Informatics Hub at Addenbrooke’s
Hospital in Cambridge.
The aim is to advance translational research studies in key disease
areas such as cancer, diabetes and neurological disorders.
The Cambridge-based hub was established with funding from the Medical
Research Council and from the University’s Clinical School and NIHR
Biomedical Research Centre to accelerate the use of genetic information
to help identify new therapies, diagnostics and preventive strategies.
Genomics and biomedical scientists will use three SOLiD 3 Plus
Systems, next-generation DNA sequencing platforms from Life
Technologies, to advance targeted medical resequencing and whole
transcriptome analysis research studies.
“We are at an exciting point in history where technologies such as
the SOLiD System, provide the throughput and accuracy required for
comprehensive characterization of disease systems,” said Professor John
Todd of the University of Cambridge and principal investigator at the
Eastern Sequence and Informatics Hub, Addenbrooke’s Hospital.
“The translation of this information into clinically relevant
knowledge will have a direct impact on the treatment of human disease
through the development of better diagnostic, prognostic and therapeutic
“The collaboration with the University of Cambridge’s Eastern
Sequence and Informatics Hub, underlines our commitment to help deliver
the potential of translational research and accelerate the realization
of personalized medicine,” said Shaf Yousaf, President, Genomic Analysis
at Life Technologies.
“The SOLiD System offers an optimized and integrated next-generation
sequencing solution to provide researchers with the required throughput,
accuracy, speed and flexibility for a wide range of genetic